title: Effects of the rhizomes of Atractylodes japonica and atractylenolide I on allergic response and experimental atopic dermatitis.
abstract: Although some anti-allergic activities of the rhizome of Atractylodes japonica have been previously reported, the active principle(s) for anti-allergic action is not fully elucidated and the effect of this plant material on atopic dermatitis (AD) is not known. In this study, the 70% ethanol extract of the rhizome of A. japonica was found to significantly inhibit 5-lipoxygenase (5-LOX)-catalyzed leukotrienes (LT) production from rat basophilic leukemia (RBL)-1 cells. From the extract of A. japonica, three major sesquiterpene derivatives including atractylenolide I, atractylenolide III and eudesma-4,7-dien-8-one were successfully isolated. Among these compounds, only atractylenolide I was shown to strongly inhibit 5-LOX from RBL-1 cells (IC(50) = 18.6 μM). To evaluate the effects of experimental AD, the ethanol extract of A. japonica (200 mg/day) was administered orally to hapten-treated NC/Nga mice which is an animal model of AD. It was firstly found that the extract significantly inhibited AD-like symptoms in mice, as judged by severity score and scratching behavior. Taken together, it is concluded that A. japonica possesses the inhibitory activity on 5-LOX and an animal model of AD, and atractylenolide I may contribute, at least in part, to these anti-allergic actions of A. japonica.
authors.affiliation: College of Pharmacy, Kangwon National University, Chunchon 200-701, Korea.
authors.forename: Hyun
authors.initials: H
authors.lastname: Lim
authors.forename: Je Hyeong
authors.initials: JH
authors.lastname: Lee
authors.forename: Jinwoong
authors.initials: J
authors.lastname: Kim
authors.forename: Yeong Shik
authors.initials: YS
authors.lastname: Kim
authors.forename: Hyun Pyo
authors.initials: HP
authors.lastname: Kim
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D001094:Arachidonate 5-Lipoxygenase / Q000187:drug effects / Q000378:metabolism; D031174:Atractylodes / Q000737:chemistry*; D045744:Cell Line, Tumor; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D020128:Inhibitory Concentration 50; D007783:Lactones / Q000302:isolation & purification / Q000494:pharmacology*; D015471:Leukemia, Basophilic, Acute / Q000201:enzymology / Q000378:metabolism; D015289:Leukotrienes / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage / Q000302:isolation & purification / Q000494:pharmacology; D008297:Male; D051379:Mice; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D027343:Rhizome; D012717:Sesquiterpenes / Q000302:isolation & purification / Q000494:pharmacology*; D012720:Severity of Illness Index
chemical_list: D018926:Anti-Allergic Agents; D007783:Lactones; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D010936:Plant Extracts; D012717:Sesquiterpenes; C424804:atractylenolide I; D001094:Arachidonate 5-Lipoxygenase